Assessment of nonischemic myocardial fibrosis
- PMID: 20620723
- DOI: 10.1016/j.jacc.2010.02.047
Assessment of nonischemic myocardial fibrosis
Abstract
Myocardial fibrosis is recognized as the pathologic entity of extracellular matrix remodeling. Diffuse, reactive fibrosis is being increasingly recognized in a variety of conditions despite the absence of ischemia. Regardless of the etiology, fibrosis leads to increased myocardial stiffness thereby promoting cardiac dysfunction. This may present clinically with symptoms of cardiac failure although often this is a subclinical disease. Various imaging modalities and collagen biomarkers have been used as surrogate markers to assess the presence, extent, and turnover of myocardial fibrosis. Techniques using echocardiography, cardiac magnetic resonance, and nuclear imaging have been developed to detect early features of systolic and diastolic left ventricular dysfunction and impaired contractile reserve. Further identification of diffuse reactive fibrosis may be possible with evolving cardiac magnetic resonance and molecular techniques. The goal of these approaches is to enable targeted therapy to be instituted earlier, leading to prevention of disease progression and fibrosis accumulation long term.
Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Myocardial fibrosis detected by cardiac magnetic resonance imaging in heart failure: impact on remodeling, diastolic function and BNP levels.Anadolu Kardiyol Derg. 2011 Feb;11(1):71-6. doi: 10.5152/akd.2011.013. Epub 2011 Jan 11. Anadolu Kardiyol Derg. 2011. PMID: 21220243 Review.
-
Targeted deletion of nuclear factor kappaB p50 enhances cardiac remodeling and dysfunction following myocardial infarction.Circ Res. 2009 Mar 13;104(5):699-706. doi: 10.1161/CIRCRESAHA.108.189746. Epub 2009 Jan 24. Circ Res. 2009. PMID: 19168865
-
[Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].Praxis (Bern 1994). 1997 Apr 2;86(14):566-74. Praxis (Bern 1994). 1997. PMID: 9198851 Review. German.
-
Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping.J Am Coll Cardiol. 2008 Nov 4;52(19):1574-80. doi: 10.1016/j.jacc.2008.06.049. J Am Coll Cardiol. 2008. PMID: 19007595
-
Biomarkers of myocardial fibrosis.J Cardiovasc Pharmacol. 2011 May;57(5):522-35. doi: 10.1097/FJC.0b013e31821823d9. J Cardiovasc Pharmacol. 2011. PMID: 21423029 Review.
Cited by
-
The Downregulation of ADAM17 Exerts Protective Effects against Cardiac Fibrosis by Regulating Endoplasmic Reticulum Stress and Mitophagy.Oxid Med Cell Longev. 2021 May 6;2021:5572088. doi: 10.1155/2021/5572088. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34035876 Free PMC article.
-
Immunosuppressants Tacrolimus and Sirolimus revert the cardiac antifibrotic properties of p38-MAPK inhibition in 3D-multicellular human iPSC-heart organoids.Front Cell Dev Biol. 2022 Nov 11;10:1001453. doi: 10.3389/fcell.2022.1001453. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36438566 Free PMC article.
-
Cardiac magnetic resonance in patients with mitral valve prolapse: Focus on late gadolinium enhancement and T1 mapping.Eur Radiol. 2019 Mar;29(3):1546-1554. doi: 10.1007/s00330-018-5634-5. Epub 2018 Aug 7. Eur Radiol. 2019. PMID: 30088066
-
Proteomic Insights into Cardiac Fibrosis: From Pathophysiological Mechanisms to Therapeutic Opportunities.Molecules. 2022 Dec 11;27(24):8784. doi: 10.3390/molecules27248784. Molecules. 2022. PMID: 36557919 Free PMC article. Review.
-
DDAH2 alleviates myocardial fibrosis in diabetic cardiomyopathy through activation of the DDAH/ADMA/NOS/NO pathway in rats.Int J Mol Med. 2019 Feb;43(2):749-760. doi: 10.3892/ijmm.2018.4034. Epub 2018 Dec 18. Int J Mol Med. 2019. PMID: 30569164 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical